CA2982125A1 - Compositions and methods for the treatment of hbv infection - Google Patents

Compositions and methods for the treatment of hbv infection Download PDF

Info

Publication number
CA2982125A1
CA2982125A1 CA2982125A CA2982125A CA2982125A1 CA 2982125 A1 CA2982125 A1 CA 2982125A1 CA 2982125 A CA2982125 A CA 2982125A CA 2982125 A CA2982125 A CA 2982125A CA 2982125 A1 CA2982125 A1 CA 2982125A1
Authority
CA
Canada
Prior art keywords
formula
compound
hbv
subject
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2982125A
Other languages
English (en)
French (fr)
Inventor
Radhakrishnan P. Iyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Star Therapeutics Inc
Original Assignee
Spring Bank Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spring Bank Pharmaceuticals Inc filed Critical Spring Bank Pharmaceuticals Inc
Publication of CA2982125A1 publication Critical patent/CA2982125A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA2982125A 2015-04-07 2016-04-07 Compositions and methods for the treatment of hbv infection Abandoned CA2982125A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562144300P 2015-04-07 2015-04-07
US62/144,300 2015-04-07
US201562220406P 2015-09-18 2015-09-18
US62/220,406 2015-09-18
US201662279382P 2016-01-15 2016-01-15
US62/279,382 2016-01-15
PCT/US2016/026498 WO2016164619A2 (en) 2015-04-07 2016-04-07 Compositions and methods for the treatment of hbv infection

Publications (1)

Publication Number Publication Date
CA2982125A1 true CA2982125A1 (en) 2016-10-13

Family

ID=57072854

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2982125A Abandoned CA2982125A1 (en) 2015-04-07 2016-04-07 Compositions and methods for the treatment of hbv infection

Country Status (10)

Country Link
US (1) US20180110796A1 (cg-RX-API-DMAC7.html)
EP (1) EP3280422A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018512428A (cg-RX-API-DMAC7.html)
KR (1) KR20170132327A (cg-RX-API-DMAC7.html)
CN (1) CN107635566A (cg-RX-API-DMAC7.html)
AU (1) AU2016244828A1 (cg-RX-API-DMAC7.html)
CA (1) CA2982125A1 (cg-RX-API-DMAC7.html)
HK (1) HK1250480A1 (cg-RX-API-DMAC7.html)
TW (1) TW201709912A (cg-RX-API-DMAC7.html)
WO (1) WO2016164619A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201821085A (zh) * 2016-10-24 2018-06-16 美商春季銀行製藥公司 用於治療hbv感染的組合物及方法
KR101899773B1 (ko) * 2017-03-07 2018-09-18 일동제약(주) 베시포비르 디피복실 또는 이의 약제학적 허용되는 염 함유 과립, 상기 과립을 포함하는 약제학적 조성물 및 이의 제조 방법
WO2020040327A1 (ko) * 2018-08-23 2020-02-27 광주과학기술원 시클로피록스의 hbv 코어조립 저해 용도
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2021016543A1 (en) * 2019-07-25 2021-01-28 Romark Laboratories L.C. Antiviral combinations of thiazolide compounds
WO2021058021A1 (zh) * 2019-09-29 2021-04-01 正大天晴药业集团股份有限公司 包含tlr7激动剂的药物组合
CN114502194A (zh) * 2019-10-02 2022-05-13 华盛顿大学 用于治疗乙型肝炎病毒感染的组合物和方法
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
KR102292147B1 (ko) * 2020-11-18 2021-08-23 주식회사 차백신연구소 경구용 항바이러스제 및 리포펩타이드와 폴리(i:c) 아쥬반트를 포함한 치료백신을 유효성분으로 포함하는 만성 b형 간염의 예방 또는 치료용 약제학적 조성물, 약제학적 병용제제, 병용제 키트
WO2022115765A1 (en) * 2020-11-30 2022-06-02 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis e virus infection with interferon lambda

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2913889A (en) * 1987-11-16 1989-06-14 Fox Chase Cancer Center Determination of anti-pol as an early marker of viral hepatitis infection
US6432966B2 (en) * 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
ES2272460T3 (es) * 2000-03-29 2007-05-01 Georgetown University L-fmau para el tratamiento de la infeccion viral hepatitis delta.
US7202354B2 (en) * 2001-03-30 2007-04-10 Abbott Laboratories Hepatitis B virus surface antigen mutant and methods of detection thereof
CA2529997A1 (en) * 2003-06-20 2004-12-29 Dade Behring Marburg Gmbh Novel surface protein (hbsag) variant of hepatitis b virus
CN101278938A (zh) * 2008-03-20 2008-10-08 黑龙江加州国际投资咨询有限公司 泰诺福韦酯和恩替卡韦的复方制剂及其抗乙肝病毒的应用
GB2471806B (en) * 2008-04-03 2012-12-19 Spring Bank Pharmaceuticals Inc Compositions and methods for treating viral infections
EP2611451A4 (en) * 2010-08-30 2014-01-15 Spring Bank Pharmaceuticals Inc DESIGN OF OLIGONUCLEOTIDE ANALOGUES AS THERAPEUTIC AGENTS

Also Published As

Publication number Publication date
WO2016164619A3 (en) 2016-12-08
CN107635566A (zh) 2018-01-26
HK1250480A1 (zh) 2018-12-21
EP3280422A4 (en) 2018-12-05
TW201709912A (zh) 2017-03-16
US20180110796A1 (en) 2018-04-26
WO2016164619A2 (en) 2016-10-13
KR20170132327A (ko) 2017-12-01
AU2016244828A1 (en) 2017-10-26
JP2018512428A (ja) 2018-05-17
EP3280422A2 (en) 2018-02-14

Similar Documents

Publication Publication Date Title
US20180110796A1 (en) Compositions and methods for the treatment of hbv infection
JP2013521279A (ja) Ｈｃｖ複製の阻害剤としての医薬併用剤
US9861679B2 (en) Method of treating cancer
JP2014532657A (ja) Ｃ型肝炎ウイルスを処置するための方法および組成物
US20220023287A1 (en) Treatment of hepatitis delta virus infection
CN108367001A (zh) 治疗丁型肝炎病毒感染
JP2020203947A (ja) Ｎｓ５ａ、ｎｓ５ｂまたはｎｓ３阻害剤を使用する、ｂ型肝炎ウイルス感染症を処置するための方法
JP2020533314A (ja) パラポックスウイルス・オヴィス（Ｐａｒａｐｏｘｖｉｒｕｓ ｏｖｉｓ：ＰＰＶＯ）、および少なくとも一つの追加の抗ウイルス薬を使用したＢ型肝炎ウイルス（ＨＢＶ）感染者の併用療法
KR20180074654A (ko) 바이러스 감염의 치료를 위한 조성물 및 방법
KR20220018552A (ko) 항 간염 바이러스 의약품 제조를 위한 암렉사녹스의 용도
JPH05507481A (ja) ウイルス性肝炎の診断及び治療
WO2016191811A1 (en) Mobilizing agents and uses therefor
US20190290673A1 (en) Compositions and methods for the treatment of hbv infection
EA038527B1 (ru) Способ лечения респираторного заболевания или состояния, композиции и наборы, содержащие двойной ингибитор киназ pi3k дельта-гамма и кортикостероид
US20080089860A1 (en) Therapeutic compositions and methods useful in treating cancer
WO2022213870A1 (zh) 通过口服给药抑制CD4+Treg细胞的药物和方法
WO2013086133A1 (en) Methods and compositions for treating viral diseases
US20190046552A1 (en) Compositions and methods for the treatment of hcv infection
Korkmaz et al. Comparison of adefovir dipivoxil and pegylated interferon alpha-2a treatment in chronic hepatitis B patients
WO2022213869A1 (zh) 通过口服给药增加病毒空衣壳蛋白治疗hbv的方法
WO2004083186A1 (ja) ウイルス性肝炎治療剤及び制癌剤
CN114555089A (zh) 用于乙型肝炎治疗的化合物
KR20070053229A (ko) 헤파드나비리대 감염을 치료 또는 예방하기 위한 조성물 및방법
JP2021134181A (ja) 抗ｂ型肝炎ウイルス剤
KR20180051794A (ko) Prk2 활성저해제 및 c형 간염바이러스의 비구조 단백질(ns5a) 표적치료제를 포함하는 간염바이러스 치료용 상승적 약학 조성물

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220301